Journal of Clinical Oncology, Vol 5, 1232-1239, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma

PH Wiernik, EL Schwartz, A Einzig, JJ Strauman, RB Lipton and JP Dutcher

Taxol, a plant product, has significant activity against certain rodent and human xenograft tumors. It promotes microtubule assembly in vitro, in contrast to vinca alkaloids, which inhibit assembly. In this phase I study, taxol was administered as a 24-hour continuous intravenous (IV) infusion in 65 courses to 26 patients. A premedication regimen of dexamethasone, cimetidine, and diphenhydramine was used to prevent the acute hypersensitivity reactions observed in previous studies of taxol. Only one episode of mild stridor occurred in this study. Peripheral neuropathy was the dose-limiting toxicity and was observed in 40% of patients treated at a dose of 250 mg/m2. Significant neutropenia of brief duration was also common. Pharmacokinetic studies by a high- performance liquid chromatography (HPLC) method demonstrated that drug plasma concentrations increased during the 24-hour infusion and then declined rapidly. Peak plasma concentrations correlated with dose, and less than 5% of taxol was excreted in the urine. Most of the drug was bound to serum components. Partial responses of more than 3 months' duration were observed in four of 12 melanoma patients treated. The recommended phase II dose of taxol on this schedule is 250 mg/m2. Priority should be given to the study of taxol in melanoma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. O'Day, R. Gonzalez, D. Lawson, R. Weber, L. Hutchins, C. Anderson, J. Haddad, S. Kong, A. Williams, and E. Jacobson Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma J. Clin. Oncol., November 10, 2009; 27(32): 5452 - 5458. [Abstract] [Full Text] [PDF]

				K. T. Flaherty, J. Schiller, L. M. Schuchter, G. Liu, D. A. Tuveson, M. Redlinger, C. Lathia, C. Xia, O. Petrenciuc, S. R. Hingorani, et al. A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel Clin. Cancer Res., August 1, 2008; 14(15): 4836 - 4842. [Abstract] [Full Text] [PDF]

				M. Joerger, A. D.R. Huitema, D. H.J.G. van den Bongard, J. H.M. Schellens, and J. H. Beijnen Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2150 - 2157. [Abstract] [Full Text] [PDF]

				D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]

				C. J. Yoon, J. W. Chung, J. H. Park, Y. H. Yoon, J. W. Lee, S. Y. Jeong, and H. Chung Transcatheter Arterial Chemoembolization with Paclitaxel-Lipiodol Solution in Rabbit VX2 Liver Tumor Radiology, October 1, 2003; 229(1): 126 - 131. [Abstract] [Full Text] [PDF]

				N. K. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R. L. Theriault, E. Rivera, B. Esmaeli, S. E. Ring, A. Bedikian, G. N. Hortobagyi, et al. Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel Clin. Cancer Res., May 1, 2002; 8(5): 1038 - 1044. [Abstract] [Full Text] [PDF]

				H. Gelderblom, K. Mross, A. J. ten Tije, D. Behringer, S. Mielke, D. M. van Zomeren, J. Verweij, and A. Sparreboom Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions J. Clin. Oncol., January 15, 2002; 20(2): 574 - 581. [Abstract] [Full Text] [PDF]

				J. P. Curtin, J. A. Blessing, K. D. Webster, P. G. Rose, A. R. Mayer, W. C. Fowler Jr, J. H. Malfetano, and R. D. Alvarez Paclitaxel, an Active Agent in Nonsquamous Carcinomas of the Uterine Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., March 1, 2001; 19(5): 1275 - 1278. [Abstract] [Full Text] [PDF]

				R. J. Schilder, J. M. Gallo, M. M. Millenson, M. A. Bookman, L. M. Weiner, A. Rogatko, B. Rogers, K. Padavic-Shallers, M. Boente, N. Rosenblum, et al. Phase I Trial of Multiple Cycles of High-Dose Carboplatin, Paclitaxel, and Topotecan With Peripheral-Blood Stem-Cell Support as Front-Line Therapy J. Clin. Oncol., February 15, 2001; 19(4): 1183 - 1194. [Abstract] [Full Text] [PDF]

				E. Brouwer, J. Verweij, P. De Bruijn, W. J. Loos, M. Pillay, D. Buijs, and A. Sparreboom Measurement of Fraction Unbound Paclitaxel in Human Plasma Drug Metab. Dispos., October 1, 2000; 28(10): 1141 - 1145. [Abstract] [Full Text] [PDF]

				D. Frame Introduction to taxane pharmacokinetics and pharmacodynamics Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S23 - S27. [Abstract] [PDF]

				W. Akerley III Paclitaxel in Advanced Non-Small Cell Lung Cancer : An Alternative High-Dose Weekly Schedule Chest, April 1, 2000; 117 (2009): 152S - 155S. [Abstract] [Full Text] [PDF]

				M. H. Woo, M. V. Relling, D. S. Sonnichsen, G. K. Rivera, C. B. Pratt, C.-H. Pui, W. E. Evans, and A. S. Pappo Phase I Targeted Systemic Exposure Study of Paclitaxel in Children with Refractory Acute Leukemias Clin. Cancer Res., March 1, 1999; 5(3): 543 - 549. [Abstract] [Full Text] [PDF]

				Y. F. Lam, C. J. Chan, and J. G Kuhn Review : Pharmacokinetics and pharmacodynamics of the taxanes Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 76 - 93. [Abstract] [PDF]

				E. K. Rowinsky and R. C. Donehower Paclitaxel (Taxol) N. Engl. J. Med., April 13, 1995; 332(15): 1004 - 1014. [Full Text] [PDF]

				Z. Sahenk, R. Barohn, P. New, and J. R. Mendell Taxol Neuropathy: Electrodiagnostic and Sural Nerve Biopsy Findings Arch Neurol, July 1, 1994; 51(7): 726 - 729. [Abstract] [PDF]

				D. L. Betcher and N. Burnham Taxol Journal of Pediatric Oncology Nursing, January 1, 1993; 10(1): 37 - 39. [PDF]

				W. P. McGuire, E. K. Rowinsky, N. B. Rosenshein, F. C. Grumbine, D. S. Ettinger, D. K. Armstrong, and R. C. Donehower Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms Ann Intern Med, August 15, 1989; 111(4): 273 - 279. [Abstract] [PDF]